

Evolving pain management: Biopsychosocial and personalized.

Ryuji S. Nakamura*

Department of Pain Medicine, University of Tokyo, Japan

Introduction

Pain neuroscience education (PNE) is crucial for managing musculoskeletal pain. It helps patients understand pain from a biopsychosocial perspective, moving beyond just the biomedical model. This shift in understanding empowers individuals, reduces pain-related fear, and ultimately improves functional outcomes. Integrating PNE into comprehensive treatment plans is strongly supported by evidence, demonstrating its effectiveness in altering pain beliefs and behaviors for better long-term management [1].

Implementing opioid-sparing strategies during total knee arthroplasty significantly reduces postoperative opioid consumption while maintaining effective pain control. These multimodal approaches, which often combine regional anesthesia with non-opioid medications, are vital for minimizing opioid-related side effects and mitigating the risk of long-term dependence. This approach contributes to improved patient recovery trajectories and overall outcomes [2].

Identifying key risk factors for chronic post-surgical pain is essential for proactive intervention. Pre-existing chronic pain, higher preoperative pain intensity, and psychological distress like anxiety or depression are strong predictors. Recognizing these factors allows clinicians to develop targeted strategies, such as enhanced psychological support or individualized analgesic regimens, aiming to prevent the persistent pain transition after surgery [3].

Pain genetics is a rapidly evolving frontier, offering insights into individual variations in pain perception and susceptibility, particularly for conditions like neuropathic pain. Understanding the genetic underpinnings of pain pathways is paving the way for personalized pain medicine. This approach promises more effective and tailored therapeutic strategies, moving beyond broad treatments to those specifically suited to a patient's genetic profile [4].

Central sensitization is a hallmark mechanism in chronic pain states, particularly chronic low back pain, characterized by heightened nervous system sensitivity. Utilizing tools such as the Central Sensitization Inventory (CSI) and Quantitative Sensory Testing (QST) is critical for accurate diagnosis and differential assessment of this phenomenon. These assessments help in tailoring treatment strate-

gies that directly address the underlying pain mechanisms, rather than just the symptoms [5].

Non-pharmacological interventions are increasingly important for managing chronic pain, offering effective alternatives or adjuncts to medication. A systematic review confirms their value, encompassing approaches like physical therapy, exercise, and cognitive-behavioral therapy. These methods are shown to reduce pain intensity and improve functional capacity, underscoring the benefits of a comprehensive, multidisciplinary strategy for chronic pain relief [6].

Enhanced Recovery After Surgery (ERAS) protocols significantly optimize post-surgical pain management and accelerate overall recovery across various surgical specialties, including spine surgery. These comprehensive pathways integrate best practices from preoperative counseling through postoperative rehabilitation, leading to reduced opioid consumption, shorter hospital stays, and fewer complications. Standardized implementation of ERAS is vital to maximize its widespread benefits [7].

Advances in pain genetics are transforming the landscape of pain management, moving from identifying underlying mechanisms to enabling precision medicine. Understanding how genetic variations influence pain perception, response to analgesics, and chronic pain risk allows for more accurate prognoses and highly individualized treatment plans. This targeted approach is poised to improve therapeutic outcomes and minimize adverse drug reactions [8].

Fear-avoidance models remain critical for understanding chronic pain, emphasizing how fear of pain drives avoidance behaviors that can perpetuate disability. However, these models need updating to integrate a broader range of biopsychosocial factors, including patient resilience, self-efficacy, and social context. Evolving these frameworks will lead to more nuanced and comprehensive approaches to chronic pain assessment and management [9].

Cannabinoids modulate pain through intricate neuropharmacological mechanisms, primarily interacting with the endocannabinoid system (ECS). This system regulates neurotransmission, inflammation, and pain perception across central and peripheral nervous systems. Ongoing research into cannabinoids is revealing their signif-

*Correspondence to: Ryuji S. Nakamura, Department of Pain Medicine, University of Tokyo, Japan. E-mail: ryuji.nakamura@tokyopainresearch.jp

Received: 01-May-2025, Manuscript No. AAPMT-25-264; Editor assigned: 05-May-2025, Pre QC No. AAPMT-25-264 (PQ); Reviewed: 23-May-2025, QC No. AAPMT-25-264; Revised: 03-Jun-2025, Manuscript No. AAPMT-25-264 (R); Published: 12-Jun-2025, DOI: 10.35841/aapmt-9.3.264

icant potential as novel therapeutic agents for various pain conditions, prompting further studies into optimal dosing and long-term safety profiles [10].

Conclusion

Pain neuroscience education (PNE) is crucial for managing musculoskeletal pain, promoting a biopsychosocial understanding that reduces fear and improves outcomes. Opioid-sparing strategies, particularly in total knee arthroplasty, successfully reduce postoperative opioid consumption and related side effects through multimodal approaches. Identifying risk factors like pre-existing pain and psychological distress is vital for preventing chronic postsurgical pain with targeted interventions. Research into pain genetics is advancing personalized pain medicine by uncovering genetic variations that influence pain perception and treatment response, especially for conditions like neuropathic pain. Central sensitization, a key mechanism in chronic pain, requires specific diagnostic tools like the Central Sensitization Inventory (CSI) and Quantitative Sensory Testing (QST) for tailored treatment. Non-pharmacological interventions, including physical therapy, exercise, and cognitive-behavioral therapy, offer effective pain reduction and functional improvement in chronic pain management. Enhanced Recovery After Surgery (ERAS) protocols significantly optimize post-surgical pain management and recovery, reducing opioid use and hospital stays across specialties. Fear-avoidance models, while crucial for understanding chronic pain, need to evolve to incorporate broader biopsychosocial factors like resilience and self-efficacy for more comprehensive management. Finally, cannabinoids are showing significant potential as novel therapeutic agents for pain by modulating the endocannabinoid system (ECS), necessitating further research

into their optimal use and safety.

References

1. Jo N, Antoon JW, Lieven DB. The role of pain neuroscience education in musculoskeletal pain: An evidence-based and expert-driven perspective on the clinical applicability. *Pain Rep.* 2023;8(2):e1078.
2. Shu-Ching C, Ken-Ching C, Yao-Hung L. Opioid-sparing strategies and outcomes in patients undergoing total knee arthroplasty: a systematic review and meta-analysis. *Ann Palliat Med.* 2023;12(4):681-697.
3. Hans JG, Esther MPZ, Erik KA. Risk factors for chronic post-surgical pain: A systematic review and meta-analysis. *Pain.* 2023;164(7):1443-1457.
4. David LB, Ioana B, Michael C. Pain genetics: a new frontier for pain medicine. *Pain.* 2019;160(Suppl 1):S1-S12.
5. Ronggang Y, Jaehyun K, Young-Sung K. Central sensitization inventory and quantitative sensory testing in the differential diagnosis of chronic low back pain. *Sci Rep.* 2023;13(1):18991.
6. Ana CM, Pablo dIC, Maria AGC. Effectiveness of Non-Pharmacological Interventions in the Treatment of Chronic Pain: A Systematic Review. *J Clin Med.* 2023;12(17):5525.
7. Jacob M, Rachel R, Dale T. Current state of enhanced recovery after surgery in spine: a systematic review and expert consensus. *Spine J.* 2023;23(9):1420-1433.
8. Junhua M, Zhenwei L, Dandan Y. Advances in pain genetics: from mechanisms to precision medicine. *J Transl Med.* 2023;21(1):798.
9. David S, Thomas P, Rob SS. Fear-avoidance models in chronic pain: Time for an update. *Pain.* 2023;164(3):477-483.
10. Arman K, Reza G, Hadi AK. Cannabinoids and pain: A review of the neuropharmacological mechanisms. *J Cannabis Res.* 2023;5(1):31.

Citation: Nakamura RS. *Evolving pain management: Biopsychosocial and personalized.* *J Pain Manage Ther.* 2025;09(03):264.